[Skip to Navigation]
Views 1,146
Citations 0
Viewpoint
March 15, 2021

Complexities of Reperfusion Therapy in Patients With Ischemic Stroke Pretreated With Direct Oral Anticoagulants: To Treat or Not, and How?

Author Affiliations
  • 1Department of Neurology, McGovern Medical School at the University of Texas Health Science Center at Houston, Houston
  • 2Houston Mobile Stroke Unit, Clinical Innovation and Research Institute at Memorial Hermann Hospital–Texas Medical Center, Houston
JAMA Neurol. Published online March 15, 2021. doi:10.1001/jamaneurol.2021.0290

A rapidly increasing proportion of patients with acute ischemic stroke who are otherwise eligible for thrombolysis are excluded from this treatment because of possible or known concomitant direct oral anticoagulant (DOAC) treatment. Because the patient has had an ischemic stroke, the patient may not be effectively anticoagulated. The choice to either reverse the DOAC, followed by treatment with tissue plasminogen activator (tPA), or follow current American Heart Association/American Stroke Association guidelines1 and not treat the patient at all, if DOAC use is suspected within the past 48 hours, is not a decision for the faint of heart or the inexperienced. In the absence of a universally available rapid test to measure DOAC activity and the lack of standardized assay thresholds, the clinician who decides to treat must speculate on the coagulation status of the patient or consider blindly administering a costly and potentially risky reversal agent to treat the patient with a thrombolytic agent. Both reversing anticoagulation that has been prescribed for a prothrombotic or emboligenic condition and administering a thrombolytic to a patient receiving a DOAC are risky choices in which convincing data one way or the other are lacking and not likely to emerge from randomized clinical trials. Yet not reversing and treating may deprive the patient of the opportunity to escape long-term disability. There are many nuances to consider that would affect this decision. This Viewpoint will highlight several areas of uncertainty that a clinician must consider with thrombolysis treatment in patients exposed to DOACs.

Limit 200 characters
Limit 25 characters
Conflicts of Interest Disclosure

Identify all potential conflicts of interest that might be relevant to your comment.

Conflicts of interest comprise financial interests, activities, and relationships within the past 3 years including but not limited to employment, affiliation, grants or funding, consultancies, honoraria or payment, speaker's bureaus, stock ownership or options, expert testimony, royalties, donation of medical equipment, or patents planned, pending, or issued.

Err on the side of full disclosure.

If you have no conflicts of interest, check "No potential conflicts of interest" in the box below. The information will be posted with your response.

Not all submitted comments are published. Please see our commenting policy for details.

Limit 140 characters
Limit 3600 characters or approximately 600 words
    ×